Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. (INMB) on April 20, 2023, covering events occurring on April 17, 2023, and April 19, 2023. The Company is an emerging growth company incorporated in Nevada, with principal executive offices in Boca Raton, Florida.
Key Financial Metrics
This filing is a current report regarding material agreements and other events; it does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Agreements
The Company entered into two significant amendments to existing exclusive license agreements on April 17, 2023:
- INKmune License Agreement Amendment: Amended the agreement with Immune Ventures, LLC to remove due diligence requirements, including obligations to use reasonable commercial efforts to bring products to market, initiate clinical trials, or file a New Drug Application (NDA) upon successful Phase III completion.
- PITT Agreement Second Amendment: Amended the agreement with the University of Pittsburgh to replace previous due diligence requirements with specific milestones: (i) the first patient dose in a Phase II Clinical Trial must occur by June 26, 2026, and (ii) marketing authorization from the FDA or foreign equivalent must be obtained by June 26, 2031. Patent rights disclosures were also updated.
Outlook, Risks, and Unusual Items
Other Events: On April 19, 2023, the Company issued a press release announcing pre-clinical data from research led by Virginia Commonwealth University and the Barrow Neurological Institute.
Risks and Contingencies: The removal of certain due diligence obligations in the INKmune agreement may alter the Company's operational roadmap for that specific asset. The PITT agreement now imposes strict long-term deadlines for clinical progression and regulatory approval.
Investor Verification Checklist
- Review the full text of the INKmune Amendment (Exhibit 10.1) to confirm the scope of removed commercialization obligations.
- Verify the specific Phase II and marketing authorization deadlines (2026 and 2031) in the Second PITT Amendment (Exhibit 10.2).
- Examine the pre-clinical data press release (Exhibit 99.1) for details on the research findings and their potential impact on the Company's pipeline.
- Confirm the Company's current cash position and runway in subsequent filings (e.g., 10-Q or 10-K), as this 8-K does not provide liquidity data.